title: Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.
abstract: Neuropilin-2 (NRP2) is a receptor expressed by tumor cells and endothelial cells (EC) that binds both semaphorin 3F (SEMA3F), a potent inhibitor of tumor angiogenesis and metastasis, and vascular endothelial growth factor (VEGF), a potent stimulator of tumor angiogenesis. It was found that glioblastoma and melanoma cells repressed NRP2 expression when maintained under hypoxic conditions and after treatment with the hypoxia-mimetic agent desferrioxamine (DFO), at both the mRNA and protein levels. Silencing of HIF1-α, the hypoxia-induced subunit of the hypoxia inducible factor (HIF), abrogated DFO-induced NRP2 repression. Conversely, ectopic expression of HIF1-α directly repressed NRP2 promoter activity and expression. NRP2 is the sole receptor for SEMA3F. Loss of NRP2 expression in tumor cells inhibited SEMA3F-dependent activities, such as inactivation of RhoA, depolymerization of F-actin, and inhibition of tumor cell migration. On the other hand, loss of NRP2 expression in tumor cells increased VEGF protein levels in conditioned media, with no effects on VEGF mRNA levels. This increase in VEGF protein levels promoted paracrine activation of EC, including VEGF receptor-2 phosphorylation, and activation of downstream signaling proteins such as p44/42 MAPK and p38 MAPK. In addition, the elevated VEGF levels induced EC migration and sprouting, two key steps of tumor angiogenesis in vivo. It was concluded that hypoxia regulates VEGF and SEMA3F activities through transcriptional repression of their common receptor NRP2, providing a novel mechanism by which hypoxia induces tumor angiogenesis, growth and metastasis.
authors: Vascular Biology Program and Department of Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA.
authors: Silvia
authors: S
authors: Coma
authors: Akio
authors: A
authors: Shimizu
authors: Michael
authors: M
authors: Klagsbrun
references: Mol Cell Biol. 1996 Sep;16(9):4604-13
references: 8756616
references: Oncogene. 2007 Aug 16;26(38):5577-86
references: 17369861
references: J Biol Chem. 2008 Oct 17;283(42):28074-80
references: 18708346
references: Clin Cancer Res. 2009 Nov 15;15(22):6763-70
references: 19887479
references: Int J Cancer. 2000 Nov 15;88(4):584-92
references: 11058875
references: J Biol Chem. 1995 Jan 20;270(3):1230-7
references: 7836384
references: Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80
references: 8897823
references: Mol Cell Biol. 1998 Jun;18(6):3112-9
references: 9584152
references: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4120-5
references: 8633026
references: Cancer Res. 2004 Feb 1;64(3):1008-15
references: 14871832
references: Exp Cell Res. 2006 Mar 10;312(5):584-93
references: 16445911
references: Int J Oncol. 2000 Aug;17(2):291-5
references: 10891538
references: Blood. 1993 Dec 15;82(12):3610-5
references: 8260699
references: Cell. 1998 Mar 20;92(6):735-45
references: 9529250
references: Crit Rev Oncol Hematol. 2006 Jul;59(1):15-26
references: 16716598
references: Mol Cancer Res. 2010 Aug;8(8):1063-73
references: 20651020
references: Nat Med. 2003 Jun;9(6):677-84
references: 12778166
references: Cancer Lett. 2006 Jan 8;231(1):1-11
references: 16356825
references: J Natl Cancer Inst. 2008 Jan 16;100(2):109-20
references: 18182619
references: Am J Surg Pathol. 2004 Mar;28(3):347-56
references: 15104297
references: FASEB J. 2000 Dec;14(15):2532-9
references: 11099472
references: EMBO J. 1998 Jun 1;17(11):3005-15
references: 9606183
references: Blood. 2008 Nov 1;112(9):3638-49
references: 18664627
references: Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):535-48
references: 15979925
references: Int J Cancer. 2000 Mar 20;89(2):167-71
references: 10754495
references: J Clin Invest. 2001 Jul;108(1):41-50
references: 11435456
references: Cancer Res. 2010 May 1;70(9):3823-32
references: 20388805
references: Hum Pathol. 2006 Nov;37(11):1414-25
references: 17010410
references: Blood. 2006 Aug 15;108(4):1243-50
references: 16621967
references: J Clin Invest. 2004 Nov;114(9):1260-71
references: 15520858
references: Oncogene. 1996 Mar 21;12(6):1289-97
references: 8649831
references: Science. 2003 Dec 12;302(5652):1975-8
references: 14671307
references: J Biol Chem. 2004 Sep 24;279(39):40337-44
references: 15271983
references: J Pathol. 2003 Jul;200(3):336-47
references: 12845630
references: Angiogenesis. 2008;11(1):31-9
references: 18283547
references: Mol Cancer Ther. 2006 May;5(5):1099-107
references: 16731741
references: Cancer Res. 2001 Aug 1;61(15):5736-40
references: 11479209
references: Am J Pathol. 2004 Jun;164(6):2139-51
references: 15161648
references: Clin Cancer Res. 2008 Dec 15;14(24):8052-60
references: 19088020
references: Leukemia. 2006 Nov;20(11):1950-4
references: 16990775
references: Genomics. 2000 Dec 1;70(2):211-22
references: 11112349
references: Angiogenesis. 2008;11(2):121-40
references: 18327686
references: Adv Exp Med Biol. 2002;515:33-48
references: 12613541
references: J Biol Chem. 2008 Oct 3;283(40):27230-8
references: 18660502
references: Blood. 2007 Mar 15;109(6):2565-70
references: 17110461
references: Cancer. 2002 Nov 15;95(10):2196-201
references: 12412174